Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.33 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.30 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12917978 | 0.81 | — | — | |
| SCHEMBL22846838 | 0.81 | — | — | |
| SCHEMBL22846607 | 0.81 | — | — | |
| SCHEMBL22846842 | 0.81 | — | — | |
| SCHEMBL22846085 | 0.78 | — | — | |
| SCHEMBL22846587 | 0.77 | COMT (0.31) | — | |
| SCHEMBL22846588 | 0.77 | — | — | |
| SCHEMBL12496718 | 0.76 | GAA (0.36) | — | |
| SCHEMBL12496473 | 0.75 | MAPT (0.37) | ESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL12496429 | 0.73 | NOTUM (0.36) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3654968-B1 | METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-3313828-B1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-07-12 | — | — | EP | disclosed |
| US-11207312-B2 | Metallo-beta-lactamase inhibitors and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2021-12-28 | — | — | US | disclosed |
| CN-107922394-B | 3-tetrazolyl-benzene-1, 2-disulfonamide derivatives as metallo-beta-lactamase inhibitors | 默沙东公司 | 2021-07-13 | — | — | CN | disclosed |
| EP-3313832-B1 | 3-TETRAZOLYL-BENZENE-1,2-DISULFONAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME (US) | 2021-02-24 | — | — | EP | disclosed |
| US-20200375987-A1 | METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. (US) | 2020-12-03 | — | — | US | disclosed |
| EP-3735242-A1 | METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | Merck Sharp&Dohme Corp. (US) | 2020-11-11 | — | — | EP | disclosed |
| EP-3654968-A1 | METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | Merck Sharp & Dohme Corp. (US) | 2020-05-27 | — | — | EP | disclosed |
| US-10544130-B2 | Metallo-beta-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-01-28 | — | — | US | disclosed |
| WO-2019135920-A1 | METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. (US) | 2019-07-11 | — | — | WO | disclosed |
| US-9839642-B2 | Beta-tetrazolyl-propionic acids as metallo-beta-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-12-12 | — | — | US | disclosed |
| US-9708336-B2 | Metallo-beta-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20170173035-A1 | BETA-TETRAZOLYL-PROPIONIC ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-06-22 | — | — | US | disclosed |
| EP-3139918-A1 | BETA-TETRAZOLYL-PROPIONIC ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-03-15 | — | — | EP | disclosed |
| WO-2016210215-A1 | 3-TETRAZOLYL-BENZENE-1,2-DISULFONAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-29 | — | — | WO | disclosed |
| WO-2016210234-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-29 | — | — | WO | disclosed |
| EP-3096754-A1 | METALLO-BETA-LACTAMASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-11-30 | — | — | EP | disclosed |
| US-20160333021-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-11-17 | — | — | US | disclosed |
| WO-2015171474-A1 | BETA-TETRAZOLYL-PROPIONIC ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-11-12 | — | — | WO | disclosed |
| WO-2015112441-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544130-B2 | Metallo-beta-lactamase inhibitors | MLX, ZFX, MMP12 | ESR1 2852/4885ESR2 3568/4885HSD17B1 227/4885 |
| US-20170173035-A1 | BETA-TETRAZOLYL-PROPIONIC ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS | MGAM, CMBL, PEPD | ESR1 3971/4885ESR2 2881/4885HSD17B1 335/4885 |
| US-20200375987-A1 | METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | SLC11A2, MMP12, LCT | ESR1 3726/4885ESR2 3730/4885HSD17B1 180/4885 |
| US-11207312-B2 | Metallo-beta-lactamase inhibitors and methods of use thereof | MLX, MMP12, SLC11A2 | ESR1 2830/4885ESR2 3358/4885HSD17B1 220/4885 |
| US-20160333021-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MGAM, MGAM2, GAA | ESR1 2730/4885ESR2 1934/4885HSD17B1 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.